Other languages Enzymatica AB

Equities

ENZY

SE0003943620

Delayed Nasdaq Stockholm Other stock markets 05:47:49 2024-07-12 am EDT			5-day change	1st Jan Change
2.5 ^SEK	-5.30%		+0.81%	-36.63%

Jun. 13	Enzymatica AB Announces Interim Results from Independent Clinical Study of Coldzyme® Show Duration of Illness Lowered by Approximately 5 Days	CI
Apr. 25	Enzymatica AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Enzymatica AB Announces Interim Results from Independent Clinical Study of Coldzyme® Show Duration of Illness Lowered by Approximately 5 Days	Jun. 13
Enzymatica AB Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25
Enzymatica AB Announces Composition of Nomination Committee	Mar. 27
Enzymatica Obtains CE Marking for ColdZyme Mouth Spray	Mar. 11
Enzymatica AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 16
Enzymatica AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07
Enzymatica’s Oral Spray Trial Reduces Viral Load in Common Colds	23-09-21
Enzymatica AB Announces Interim Report from Clinical Study: ColdZyme Significantly Reduces Rhinovirus Viral Load and Symptoms of Sore Throat	23-09-21
Enzymatica AB Announces New Study	23-08-22
Enzymatica AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-18
Enzymatica AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27
Enzymatica AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-17
Enzymatica AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-17
Enzymatica AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-02
Enzymatica Surges 35% After New Study Confirms ColdZyme Stops Omicron From Infecting Human Cells	22-11-01
Enzymatica Raises $7 Million Via Rights Issue	22-08-26
Enzymatica To Boost Financial Position Via $7 Million Rights Offering	22-07-19
Enzymatica AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-07-19
Enzymatica AB Announces New Data from an Ongoing In-Vitro Study	22-06-23
Enzymatica AB Appoints Moa Fransson as New Member of the Board	22-04-28

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Enzymatica AB

Equities

ENZY

SE0003943620

Other languages

Filters